Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 161.57B -7.9% |
| Revenue (ttm) | 44.65B +5.7% |
| Net Income | 15.14B +9.1% |
| EPS | 3.41 +9.2% |
| Shares Out | n/a |
| PE Ratio | 10.78 |
| Forward PE | 12.13 |
| Dividend | 1.57 (4.26%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 53,648 |
| Open | 37.14 |
| Previous Close | 37.11 |
| Day's Range | 36.30 - 37.41 |
| 52-Week Range | 30.24 - 54.87 |
| Beta | 0.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Novo Nordisk Commits $200 Million To Expand Diabetes Prevention And Care In Developing
(RTTNews) - Novo Nordisk (NVO) has pledged $200 million over the next 10 years to support the World Diabetes Foundation (WDF) in expanding diabetes prevention and care programs across low-and middle-i...
Novo commits $200 million to the World Diabetes Foundation
Novo Nordisk said on Wednesday it will commit $200 million to the World Diabetes Foundation over 10 years starting 2027, supporting the organization's work to strengthen diabetes prevention and care i...
FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – w...
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
The US Food and Drug Administration (FDA) told makers of popular weight-loss GLP-1 drugs that they must add warning labels about a rare eye condition that can cause sudden blindness. Manufacturers of ...
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
These stocks have been going in different directions over the past year, but that trend may not necessarily continue.
The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.
The updated labeling covers Mounjaro, Zepbound, Ozempic and Wegovy.
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of the...
FDA orders blindness risk warning on weight loss drugs
Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administrati...
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
U.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.
Lilly's Foundayo pill cuts sleep apnea severity by up to 44% in late-stage trial, with an FDA filing planned by year-end
Eli Lilly's daily obesity pill Foundayo cut breathing interruptions during sleep by up to 44% in a year-long Phase 3 program. Lilly plans to seek U.S. approval for obstructive sleep apnea by the end o...
US FDA orders new eye risk warnings for Ozempic, Zepbound
The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and diabetes...
Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?
GLP-1 medications and dietary supplements could play complementary roles in managing obesity and supporting longer-term health, Novonesis CEO Ester Baiget told CNBC on Monday. "We have scientific evi...
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.
Novo entered the GLP-1 space ahead of Lilly, but has since lost its lead. Both of these players launched new GLP-1 drugs, the first in pill form, this year.
Novartis drops heart drug after it failed to prevent heart attacks
Novartis is ending development of pelacarsen in heart disease. In a study of more than 8,300 patients the drug cut Lp(a) levels by 78% but did not reduce heart attacks or strokes.
Wegovy's making WAVES as weight loss drug demand surges
Novo Nordisk President and CEO Mike Doustdar discusses the success of the Wegovy weight loss pill. He explains how high efficacy and convenience are driving earnings.
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?
Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.
What Novo Nordisk A/S (NVO) Said on Its Q3 Earnings Call
Novo Nordisk A/S NYSE: NVO raised its 2026 sales and profit outlook after third-quarter adjusted sales rose 4% to DKK 79.2 billion, supported by demand for its obesity treatments and expanding use of ...
Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?
Novo got a much-needed boost from its latest earnings report.
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
An experimental Novartis drug designed to treat a genetic cause of heart disease failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several such drugs in clinical tria...
Novo Nordisk announces new real-world data from PLATINUM-Truveta, RHODIUM-2
Novo Nordisk (NVO) announced new real-world data from PLATINUM-Truveta and RHODIUM-2, which are two retrospective studies evaluating associations between semaglutide 2.4 mg once-weekly injection use v...
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at si...
Lexicon (LXRX) Q3 2026 Earnings Call Transcript
Novo Nordisk milestone payment shapes quarter as HCM readout nears.